T. Walters

发表

Duration of IOP Reduction With Travoprost BAK-free Solution

R. Gross, J. Peace, H. Dubiner, 2008, Journal of glaucoma.

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study

J. Boyer, R. Fechtner, A. Kothe, 2022, Journal of glaucoma.

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial

G. Schwartz, R. Schiffman, T. Mundorf, 2013, British Journal of Ophthalmology.

Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.

R. Schiffman, Robert D. Williams, T. Walters, 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

OPTH_A_295008 1647..1657

T. Walters, R. Lehmann, R. Fong, 2021 .

An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations

T. Walters, P. Cockrum, Robert J Smyth-Medina, 2018, Clinical ophthalmology.

Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.

H. D. Cavanagh, W. A. Maxwell, T. Walters, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy

Rishi P. Singh, G. Jaffe, K. Sall, 2012, Clinical ophthalmology.

Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.

J. Peace, T. Walters, J. Gow, 2014, Ophthalmology.

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.

H. Dubiner, A. Vandenburgh, T. Walters, 2004, Survey of ophthalmology.

Brimonidine tartrate: a one-month dose response study.

J. Schuman, A. Robin, R. Derick, 1997, Ophthalmology.

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.

T. Walters, 1996, Survey of ophthalmology.

The effect of stromal hydration on surgical outcomes for cataract patients who received a hydrogel ocular bandage

T. Walters, 2011, Clinical ophthalmology.

Sustained‐release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery

S. Masket, J. Levenson, M. Endl, 2015, Journal of cataract and refractive surgery.

Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza™): results of a qualitative survey

J. Talamo, J. L. Metzinger, J. Gira, 2017, Patient preference and adherence.

Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.

S. Lane, R. Lindstrom, R. Faulkner, 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Tear Concentration and Safety of Levofloxacin Ophthalmic Solution 1.5% Compared With Ofloxacin Ophthalmic Solution 0.3% After Topical Administration in Healthy Adult Volunteers

M. Holdbrook, T. Walters, M. Rinehart, 2010, Cornea.

Once‐daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study

Satish S. Modi, B. Philipson, C. Traverso, 2014, Journal of cataract and refractive surgery.

Rotational Stability of the Clareon Monofocal Aspheric Hydrophobic Acrylic Intraocular Lens 6 Months After Implantation

Satish S. Modi, Vidhyapriya Sreenivasan, John W. French, 2022, Clinical ophthalmology.

Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies

J. Hovanesian, J. Levenson, R. Noecker, 2016 .

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

M. Coote, R. Lewis, T. Aung, 2019, Drugs.

Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.

M. Coote, R. Lewis, S. Mansberger, 2017, American journal of ophthalmology.

Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).

Mujtaba A. Qazi, J. Levenson, M. Coote, 2020, Ophthalmology.

Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension.

C. Liss, T. Walters, D. Hartenbaum, 1998, Clinical therapeutics.

Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification

Terry Kim, R. Lindstrom, G. Demopulos, 2014, Clinical ophthalmology.

A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.

S. Mallick, T. Walters, R. Evans, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample

T. Walters, R. Lehmann, R. Fong, 2021, Clinical ophthalmology.

Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.

R. Lewis, I. Ahmed, T. Walters, 2019, Ophthalmology Glaucoma.

Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

S. Mansberger, T. Navrátil, B. Yerxa, 2017 .

Brimonidine and pupillary diameter: Authors’ reply

J. Schuman, A. Robin, R. Derick, 1998 .

Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.

J. Peace, T. Walters, J. Gow, 2014, Ophthalmology.

Mydriasis with micro-array print touch-free tropicamide-phenylephrine fixed combination MIST: pooled randomized Phase III trials.

T. Ianchulev, Siddarth Rathi, D. Wirta, 2021, Therapeutic delivery.

Reply: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac

T. Walters, 2008 .

Clinical Ophthalmology Dovepress Dovepress Intracameral Phenylephrine and Ketorolac Injection (oms302) for Maintenance of Intraoperative Pupil Diameter and Reduction of Postoperative Pain in Intraocular Lens Replacement with Phacoemulsification

Terry Kim, R. Lindstrom, T. Walters, 2022 .